HY-165034 Search Results


glucosylceramide synthase gcs  (MedChemExpress)
90
MedChemExpress glucosylceramide synthase gcs
FIGURE 1 ETBF, through BFT, increases <t>glucosylceramide</t> levels in mice and in colonoids. Colonization with C57BL/6J mice for 1 week with ETBF increases glucosylceramide levels in the distal colon (A). Treatment of colonoids with concentrated bacterial culture supernatant from ETBF (BFT) significantly increases glucosylceramide levels at 24 h when compared to concentrated bacterial supernatant from ETBFΔbft (Control) (B). Addition of purified Bacteroides fragilis toxin (Purified BFT2, isolated from ETBF strain 86-5443-2-2, see Materials and Methods for details) to colonoids increases glucosylceramide production (C). Treatment of colonoids with BFT increases mRNA expression of glucosylceramide <t>synthase</t> (GCS) at 3 and 6 h, as measured by qPCR (D). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: *P < .05, **P < .01, or ***P < .001. Error bars represent the standard deviation of the mean. Sham represents PBS control. NT indicates no treatment was added. Control represents concentrated bacterial culture supernatant from ETBFΔbft, BFT represents concentrated bacterial culture supernatant from ETBF, and Purified BFT2 represents purified BFT from ETBF strain 86-5443-2-2 (see Materials and Methods)
Glucosylceramide Synthase Gcs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glucosylceramide synthase gcs/product/MedChemExpress
Average 90 stars, based on 1 article reviews
glucosylceramide synthase gcs - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
treosulfan  (MedChemExpress)
92
MedChemExpress treosulfan
FIGURE 1 ETBF, through BFT, increases <t>glucosylceramide</t> levels in mice and in colonoids. Colonization with C57BL/6J mice for 1 week with ETBF increases glucosylceramide levels in the distal colon (A). Treatment of colonoids with concentrated bacterial culture supernatant from ETBF (BFT) significantly increases glucosylceramide levels at 24 h when compared to concentrated bacterial supernatant from ETBFΔbft (Control) (B). Addition of purified Bacteroides fragilis toxin (Purified BFT2, isolated from ETBF strain 86-5443-2-2, see Materials and Methods for details) to colonoids increases glucosylceramide production (C). Treatment of colonoids with BFT increases mRNA expression of glucosylceramide <t>synthase</t> (GCS) at 3 and 6 h, as measured by qPCR (D). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: *P < .05, **P < .01, or ***P < .001. Error bars represent the standard deviation of the mean. Sham represents PBS control. NT indicates no treatment was added. Control represents concentrated bacterial culture supernatant from ETBFΔbft, BFT represents concentrated bacterial culture supernatant from ETBF, and Purified BFT2 represents purified BFT from ETBF strain 86-5443-2-2 (see Materials and Methods)
Treosulfan, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/treosulfan/product/MedChemExpress
Average 92 stars, based on 1 article reviews
treosulfan - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

Image Search Results


FIGURE 1 ETBF, through BFT, increases glucosylceramide levels in mice and in colonoids. Colonization with C57BL/6J mice for 1 week with ETBF increases glucosylceramide levels in the distal colon (A). Treatment of colonoids with concentrated bacterial culture supernatant from ETBF (BFT) significantly increases glucosylceramide levels at 24 h when compared to concentrated bacterial supernatant from ETBFΔbft (Control) (B). Addition of purified Bacteroides fragilis toxin (Purified BFT2, isolated from ETBF strain 86-5443-2-2, see Materials and Methods for details) to colonoids increases glucosylceramide production (C). Treatment of colonoids with BFT increases mRNA expression of glucosylceramide synthase (GCS) at 3 and 6 h, as measured by qPCR (D). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: *P < .05, **P < .01, or ***P < .001. Error bars represent the standard deviation of the mean. Sham represents PBS control. NT indicates no treatment was added. Control represents concentrated bacterial culture supernatant from ETBFΔbft, BFT represents concentrated bacterial culture supernatant from ETBF, and Purified BFT2 represents purified BFT from ETBF strain 86-5443-2-2 (see Materials and Methods)

Journal: The FASEB Journal

Article Title: Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin‐induced colon epithelial cell signaling

doi: 10.1096/fj.202001669r

Figure Lengend Snippet: FIGURE 1 ETBF, through BFT, increases glucosylceramide levels in mice and in colonoids. Colonization with C57BL/6J mice for 1 week with ETBF increases glucosylceramide levels in the distal colon (A). Treatment of colonoids with concentrated bacterial culture supernatant from ETBF (BFT) significantly increases glucosylceramide levels at 24 h when compared to concentrated bacterial supernatant from ETBFΔbft (Control) (B). Addition of purified Bacteroides fragilis toxin (Purified BFT2, isolated from ETBF strain 86-5443-2-2, see Materials and Methods for details) to colonoids increases glucosylceramide production (C). Treatment of colonoids with BFT increases mRNA expression of glucosylceramide synthase (GCS) at 3 and 6 h, as measured by qPCR (D). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: *P < .05, **P < .01, or ***P < .001. Error bars represent the standard deviation of the mean. Sham represents PBS control. NT indicates no treatment was added. Control represents concentrated bacterial culture supernatant from ETBFΔbft, BFT represents concentrated bacterial culture supernatant from ETBF, and Purified BFT2 represents purified BFT from ETBF strain 86-5443-2-2 (see Materials and Methods)

Article Snippet: In order to inhibit glucosylceramide synthase (GCS) in colonoids, ibiglustat (Venglustat, Sanofi Genzyme; obtained from MedChemExpress HY-16743) was resuspended in DMSO, diluted using CMGF- media, and used at a final concentration of 5 μmol/L.

Techniques: Control, Purification, Isolation, Expressing, Standard Deviation

FIGURE 2 A selective inhibitor of glucosylceramide synthase (GCS) decreases glucosylceramide lipid levels. The treatment regimen for the administration of 5 µmol/L ibiglustat to colonoids is depicted (A). Addition of 5 µmol/L ibiglustat effectively reduced total levels of glucosylceramide (B). Colonoids were pre-treated with 5 µmol/L ibiglustat for 24 h and then treated with C6-ceramide nanoliposomes (CNL) for 1 hour to determine the effectiveness of ibiglustat in blocking GCS activity. Colonoids were collected and lipids were extracted. Presence of ibiglustat completely blocks the ability for colonoids to process C6-ceramide into C6-glucosylceramide, demonstrating the efficacy of ibiglustat at inhibiting GCS activity (C). Pre-treatment of colonoids with 5 µmol/L ibiglustat followed by the addition of concentrated bacterial supernatant from ETBFΔbft does not alter colonoid morphology, visualized by confocal microscopy (D). The treatment regimen for the administration of 5 µmol/L ibiglustat and concentrated bacterial culture supernatant is depicted (E). Single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: ***P < .001. Error bars represent the standard deviation of the mean. Vehicle represents vehicle control (see Materials and Methods). Confocal images were captured using 10x magnification. Scale bar indicates a distance of 100 μm

Journal: The FASEB Journal

Article Title: Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin‐induced colon epithelial cell signaling

doi: 10.1096/fj.202001669r

Figure Lengend Snippet: FIGURE 2 A selective inhibitor of glucosylceramide synthase (GCS) decreases glucosylceramide lipid levels. The treatment regimen for the administration of 5 µmol/L ibiglustat to colonoids is depicted (A). Addition of 5 µmol/L ibiglustat effectively reduced total levels of glucosylceramide (B). Colonoids were pre-treated with 5 µmol/L ibiglustat for 24 h and then treated with C6-ceramide nanoliposomes (CNL) for 1 hour to determine the effectiveness of ibiglustat in blocking GCS activity. Colonoids were collected and lipids were extracted. Presence of ibiglustat completely blocks the ability for colonoids to process C6-ceramide into C6-glucosylceramide, demonstrating the efficacy of ibiglustat at inhibiting GCS activity (C). Pre-treatment of colonoids with 5 µmol/L ibiglustat followed by the addition of concentrated bacterial supernatant from ETBFΔbft does not alter colonoid morphology, visualized by confocal microscopy (D). The treatment regimen for the administration of 5 µmol/L ibiglustat and concentrated bacterial culture supernatant is depicted (E). Single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: ***P < .001. Error bars represent the standard deviation of the mean. Vehicle represents vehicle control (see Materials and Methods). Confocal images were captured using 10x magnification. Scale bar indicates a distance of 100 μm

Article Snippet: In order to inhibit glucosylceramide synthase (GCS) in colonoids, ibiglustat (Venglustat, Sanofi Genzyme; obtained from MedChemExpress HY-16743) was resuspended in DMSO, diluted using CMGF- media, and used at a final concentration of 5 μmol/L.

Techniques: Blocking Assay, Activity Assay, Confocal Microscopy, Standard Deviation, Control

FIGURE 4 Inhibition of GBA increases glucosylceramide levels but does not alter colonoid morphology. Colonoids treated with 20 μmol/L CBE for 24 h or 1 week have increased levels of glucosylceramide (A). Colonoids cultured in CBE were treated according to the treatment regimen in Figure 2E and collected at 24 h post-concentrated bacterial culture supernatant addition for lipid analysis. Total glucosylceramide levels were similar between control and BFT treatments, but were significantly decreased in the presence of 5 µmol/L ibiglustat (B). Colonoids treated with concentrated bacterial culture supernatant from ETBFΔbft and cultured in CBE did not display any obvious morphological changes when visualized by confocal microscopy (C). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: **P < .01 or ***P < .001. NS indicates non-significant results. Error bars represent the standard deviation of the mean. Vehicle indicates a vehicle control was used (see Materials and Methods). Control represents concentrated bacterial culture supernatant from ETBFΔbft and BFT represents concentrated bacterial culture supernatant from ETBF. Confocal images were captured using 10x magnification. Scale bar indicates a distance of 100 μm

Journal: The FASEB Journal

Article Title: Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin‐induced colon epithelial cell signaling

doi: 10.1096/fj.202001669r

Figure Lengend Snippet: FIGURE 4 Inhibition of GBA increases glucosylceramide levels but does not alter colonoid morphology. Colonoids treated with 20 μmol/L CBE for 24 h or 1 week have increased levels of glucosylceramide (A). Colonoids cultured in CBE were treated according to the treatment regimen in Figure 2E and collected at 24 h post-concentrated bacterial culture supernatant addition for lipid analysis. Total glucosylceramide levels were similar between control and BFT treatments, but were significantly decreased in the presence of 5 µmol/L ibiglustat (B). Colonoids treated with concentrated bacterial culture supernatant from ETBFΔbft and cultured in CBE did not display any obvious morphological changes when visualized by confocal microscopy (C). Group comparisons were performed using a one-way ANOVA and Tukey's multiple comparisons test, while single comparisons were made using an unpaired t-test. Statistical significance is indicated by asterisks: **P < .01 or ***P < .001. NS indicates non-significant results. Error bars represent the standard deviation of the mean. Vehicle indicates a vehicle control was used (see Materials and Methods). Control represents concentrated bacterial culture supernatant from ETBFΔbft and BFT represents concentrated bacterial culture supernatant from ETBF. Confocal images were captured using 10x magnification. Scale bar indicates a distance of 100 μm

Article Snippet: In order to inhibit glucosylceramide synthase (GCS) in colonoids, ibiglustat (Venglustat, Sanofi Genzyme; obtained from MedChemExpress HY-16743) was resuspended in DMSO, diluted using CMGF- media, and used at a final concentration of 5 μmol/L.

Techniques: Inhibition, Cell Culture, Control, Confocal Microscopy, Standard Deviation

FIGURE 10 A proposed mechanism for the role of glucosylceramide in response to BFT. In a healthy colon, normal microbiota persists, cells maintain normal levels of glucosylceramide, and adherens junctions and tight junctions ensure cell-to-cell adhesion (A). When the host is colonized with ETBF, ETBF joins the microbiota and begins producing BFT, causing a decrease in CEC E-cadherin levels and an increase in glucosylceramide synthase expression (B). If glucosylceramide synthase is inhibited in a host colonized with ETBF, E-cadherin and tight junction protein 1 levels decrease, which leads to an increase in membrane permeability. Bacterial factors are able to pass through the membrane and interact with host immune cells in the lamina propria, triggering a Th17-driven pro-inflammatory immune response (C). Colonization with ETBF in the presence of CBE protects tight junctions and reduces membrane permeability (D)

Journal: The FASEB Journal

Article Title: Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin‐induced colon epithelial cell signaling

doi: 10.1096/fj.202001669r

Figure Lengend Snippet: FIGURE 10 A proposed mechanism for the role of glucosylceramide in response to BFT. In a healthy colon, normal microbiota persists, cells maintain normal levels of glucosylceramide, and adherens junctions and tight junctions ensure cell-to-cell adhesion (A). When the host is colonized with ETBF, ETBF joins the microbiota and begins producing BFT, causing a decrease in CEC E-cadherin levels and an increase in glucosylceramide synthase expression (B). If glucosylceramide synthase is inhibited in a host colonized with ETBF, E-cadherin and tight junction protein 1 levels decrease, which leads to an increase in membrane permeability. Bacterial factors are able to pass through the membrane and interact with host immune cells in the lamina propria, triggering a Th17-driven pro-inflammatory immune response (C). Colonization with ETBF in the presence of CBE protects tight junctions and reduces membrane permeability (D)

Article Snippet: In order to inhibit glucosylceramide synthase (GCS) in colonoids, ibiglustat (Venglustat, Sanofi Genzyme; obtained from MedChemExpress HY-16743) was resuspended in DMSO, diluted using CMGF- media, and used at a final concentration of 5 μmol/L.

Techniques: Expressing, Membrane, Permeability